Petri Nykvist Integrins As Cellular Receptors for Fibril-Forming And

Total Page:16

File Type:pdf, Size:1020Kb

Petri Nykvist Integrins As Cellular Receptors for Fibril-Forming And Copyright © , by University of Jyväskylä ABSTRACT Nykvist, Petri Integrins as cellular receptors for fibril-forming and transmembrane collagens Jyväskylä: University of Jyväskylä, 2004, 127 p. (Jyväskylä Studies in Biological and Environmental Science, ISSN 1456-9701; 137) ISBN 951-39-1773-8 Yhteenveto: Integriinit reseptoreina fibrillaarisille ja transmembraanisille kollageeneille Diss. The two integrin-type collagen receptors α1β1 and α2β1 integrins are structurally very similar. However, cells can concomitantly express both receptors and it has been shown that these collagen receptor integrins have distinct signaling functions, and their binding to collagen may lead to opposite cellular responses. In this study, fibrillar collagen types, I, II, III, and V, and network like structure forming collagen type IV tested were recognized by both integrins at least at the αI domain level. The αI domain recognition does not always lead for cell spreading behavior. In addition transmembrane collagen type XIII was studied. CHO-α1β1 cells could spread on recombinant human collagen type XIII, unlike CHO-α2β1 cells. This finding was supported by αI domain binding studies. The results indicate, that α1β1 and α2β1 integrins do have different ligand binding specificities and distinct collagen recognition mechanisms. A common structural feature in the collagen binding αI domains is the presence of an extra helix, named helix αC. A αC helix deletion reduced affinity for collagen type I when compared to wild-type α2I domain, which indicated the importance of helix αC in collagen type I binding. Further, point mutations in amino acids Asp219, Asp259, Asp292 and Glu299 resulted in weakened affinity for collagen type I. Cells expressing double mutated α2Asp219/Asp292 integrin subunit showed remarkably slower spreading on collagen type I, while spreading on collagen type IV was not affected. The data indicated that α2I domain binds to collagen type I with a different mechanism than binding to collagen type IV. In tissues collagen monomers form large fibrils immediately after they have been released from cells. The α2I domain binding data indicate that fibril formation affects the binding constant and at the same time reduces the number of putative binding sites available to the integrins. However, integrin α2β1 could still mediate spreading on fibrillar collagen and the contraction of floating collagen gels. The α1β1 cells could neither adequately spread on collagen fibrils nor mediate the contraction of collagen gels. These findings indicate that α2β1 integrin is a functional cellular receptor for collagen fibrils, while α1β1 integrin may only bind collagen monomers effectively. Type XVII collagen, containing large collagenous domain called COL15, is a keratinocyte protein in hemidesmosomes or as soluable form in extracellular space. Assays showed that, unlike other collagens, COL15 was not recognized by the collagen receptors. Instead, the spreading on denatureted COL15 was mediated by α5β1 and αVβ1 integrins and inhibited by KGD-containing synthetic peptides. This suggests that the COL15 domain of collagen type XVII represents a specific collagenous structure, unable to interact with the cellular receptors for other collagens. After being shed from the cell surface it may support keratinocyte spreading and migration. Key words: Collagen fibrils; collagen monomers; integrin-type collagen receptors; transmembrane collagens. P. Nykvist, University of Jyväskylä, Department of Biological and Environmental Science, P.O. Box 35, FIN-40014 University of Jyväskylä, Finland Author’s address Petri Nykvist Department of Biological and Environmental Science P.O. Box 35 University of Jyväskylä FIN-40014 University of Jyväskylä Finland E-mail:[email protected] Supervisors Professor Jyrki Heino, M. D., Ph. D. Department of Biological and Environmental Science P.O. Box 35 University of Jyväskylä FIN-40014 University of Jyväskylä Finland Docent Jarmo Käpylä, Ph. D. Department of Biological and Environmental Science P.O. Box 35 University of Jyväskylä FIN-40014 University of Jyväskylä Finland Reviewers Docent Vuokko Kovanen, Ph. D. Department of Health Sciences P.O. Box 35 University of Jyväskylä FIN-40014 University of Jyväskylä Finland Docent Anna-Marja Säämänen, Ph. D. Department of Medical Biochemistry and Molecular Biology University of Turku FIN-20014 University of Turku Finland Opponent Docent Johanna Myllyharju, Ph. D. Department of Medical Biochemistry and Molecular Biology University of Oulu P.O. Box 5000 FIN-90014 University of Oulu Finland CONTENTS ABSTRACT LIST OF ORIGINAL PUBLICATIONS ABBREVIATIONS 1 INTRODUCTION ............................................................................................. 11 2 REVIEW OF LITERATURE.............................................................................. 13 2.1 Family of collagens................................................................................ 13 2.1.1 Fibrillar collagen ...................................................................... 14 2.1.1.1 Synthesis of fibril-forming collagens ..................... 14 2.1.1.2 Monomeric family members in fibrils ................... 16 2.1.1.3 Fibrillogenesis and fibrils formed – a collagenous puzzle ............................................... 19 2.1.2 Non-fibrillar collagens............................................................. 25 2.1.2.1 Network-forming collagens - collagen IV as prototype ................................................................. 25 2.1.2.2 Transmembrane collagens ..................................... 26 2.2 Family of integrins................................................................................. 32 2.2.1 Integrins in the beginning ....................................................... 32 2.2.2 Integrins presently ................................................................... 33 2.2.3 Collagen binding integrins...................................................... 34 2.2.3.1 Integrin α1β1 - binding preference to collagen type I. ........................................................ 34 2.2.3.2 Integrin α2β1 - a primary receptor for collagen type I ........................................................ 36 2.2.3.3 Integrins α10β1 and α11β1 - novel family members .................................................................. 38 2.2.4 Structure of integrins - a handshake between the subunits..................................................................................... 43 2.2.4.1 Integrin α subunit - a ground for collagen bing .......................................................................... 45 2.2.4.1.1 The αI domain structure ..................... 46 2.2.4.1.2 Integrin-collagen interaction – a cocrystal............................................. 49 2.2.4.2 Integrin β1 subunit with βI like domain............... 52 3 AIMS OF THE STUDY..................................................................................... 54 4 MATERIALS AND METHODS ...................................................................... 55 4.1 Preparation of collagens........................................................................ 55 4.1.1 Generation of recombinant ectodomain of human collagen type XIII (I) .............................................................. 55 4.1.2 Generation of recombinant COL15 domain of human collagen type XVII (IV) ......................................................... 56 4.1.3 In vitro collagen type I fibrillogenesis (III) ........................... 56 4.2 Studies on integrin αI domain - collagen interaction (I-IV).............. 56 4.2.1 Generation of human recombinant integrin α1I and α2I domains (IV) ...................................................... 56 4.2.2 Generation of mutated α2I domains (II) .............................. 57 4.2.3 Generation of human recombinant α10I domain as MBP-fusion protein (IV) ........................................................ 58 4.2.4 Direct Europium labeling of αI domains (I, II) .................... 58 4.2.5 Binding assay for directly Europium labeled αI domains (I, II) ..................................................................... 59 4.2.6 Binding assay for αI domains as GST and MBP fusion proteins (III, IV) ................................................. 59 4.2.7 Electron microscopy to study collagen type I fibril - αI domain interaction (III) ..................................................... 60 4.2.8 IAsys and BIAcore biosensor experiments (II) .................... 60 4.2.9 Molecular modeling (II) ......................................................... 60 4.3 Studies on cell - collagen interaction (I-IV) ........................................ 61 4.3.1 Transfection of CHO cells to express α1β1 or α2β1 integrins (I-IV) ............................................................... 61 4.3.2 Generation of CHO cell lines to express mutated α2β1 integrins (II, III) ............................................................. 61 4.3.3 Cell spreading assays (I-IV) ................................................... 62 4.3.4 Collagen gel contraction assay (III) ...................................... 63 4.3.5 Lateral cell migration assay (IV) ........................................... 63 5 RESULTS.......................................................................................................... 64 5.1 Collagen binding profile of α1β1 integrin is different than α2β1 integrin (I) ........................................................................... 64 5.1.1 Methods
Recommended publications
  • Innate Pro–B-Cell Progenitors Protect Against Type 1 Diabetes By
    Innate pro–B-cell progenitors protect against type 1 PNAS PLUS diabetes by regulating autoimmune effector T cells Ruddy Montandona,b,1, Sarantis Korniotisa,b,1, Esther Layseca-Espinosaa,b,2, Christophe Grasa,b, Jérôme Mégretc, Sophie Ezinea,d, Michel Dya,b, and Flora Zavalaa,b,3 aFaculté de Médecine Site Necker, Université Paris Descartes, bCentre National de la Recherche Scientifique Unité Mixte de Recherche 8147, 75015 Paris, France; cInstitut Fédératif de Recherche 94 Necker-Enfants Malades, 75015 Paris, France; and dInstitut National de la Santé et de la Recherche Médicale U1020, 75015 Paris, France Edited by Simon Fillatreau, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, and accepted by the Editorial Board May 6, 2013 (received for review December 24, 2012) Diverse hematopoietic progenitors, including myeloid populations emergence of regulatory B cells (Bregs), along with acquired-type arising in inflammatory and tumoral conditions and multipotent stimulation, such as B-cell receptor (BCR) engagement concomi- cells, mobilized by hematopoietic growth factors or emerging during tant or not with CD40 activation (10, 11). Such induced regulatory parasitic infections, display tolerogenic properties. Innate immune B-cell functions are believed to be more robust than those ex- stimuli confer regulatory functions to various mature B-cell subsets pressed by naive and resting B cells, which can nevertheless tolerize but immature B-cell progenitors endowed with suppressive proper- naive T cells and induce regulatory T cells (Tregs) (12, 13). ties per se or after differentiating into more mature regulatory Bregs are a heterogeneous lymphocyte subset present among all B cells remain to be characterized. Herein we provide evidence for major B-cell populations (14–17).
    [Show full text]
  • 2021 Undergraduate Research Symposium Program
    FORDHAM COLLEGE AT ROSE HILL 14TH ANNUAL UNDERGRADUATE RESEARCH SYMPOSIUM Wednesday, May 5, 2021 AN INTERDISCIPLINARY CELEBRATION OF OUR STUDENTS AND MENTORS The Fourteenth Annual Fordham College at Rose Hill Undergraduate Research Symposium Program | Spring 2021 Welcome to the Fourteenth Annual FCRH Research Symposium, for the first time in a hybrid format! The accomplishments of our students and mentors during the pandemic have been extraordinary and we are overjoyed to celebrate them today. From our beautiful campus, to their homes throughout the country and beyond, our undergraduate research community was always open for new discoveries. We are delighted to share 120 abstracts from over 200 students who pursued their projects during such challenging times. Their work, dedication, and determination to be a part of today’s event is inspiring and what FCRH undergraduate research is all about. We are in this together to urge each other on and findings shared today may well change the world. We are also proud to announce that the 11th volume of the Fordham Undergraduate Research Journal has been published. The FURJ team took on an enormous undertaking of running their operation in hybrid format, with a record number of submissions, and as always, they have dazzled us with the quality of their efforts. Undergraduate research has become a part of who we are at FCRH. Because of this, our program, against all odds in the past year, continues to grow, expanding across disciplines and accessible to all students in a number of ways. Students are creating new knowledge in our labs, independently with the guidance of their mentors, as part of innovative class projects, and even to support their activism.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Integrin Alpha 2 Antibody
    Product Datasheet Integrin alpha 2 Antibody Catalog No: #49071 Package Size: #49071-1 50ul #49071-2 100ul Orders: [email protected] Support: [email protected] Description Product Name Integrin alpha 2 Antibody Host Species Rabbit Clonality Monoclonal Clone No. SN0752 Purification ProA affinity purified Applications WB, ICC/IF, IHC, IP, FC Species Reactivity Hu, Ms, Rt Immunogen Description recombinant protein Other Names BR antibody CD 49b antibody CD49 antigen like family member B antibody CD49 antigen-like family member B antibody CD49b antibody CD49b antigen antibody Collagen receptor antibody DX5 antibody Glycoprotein Ia deficiency included antibody GP Ia antibody GP Ia deficiency, included antibody GPIa antibody HPA 5 included antibody HPA5 included antibody Human platelet alloantigen system 5 antibody Integrin alpha 2 antibody Integrin alpha-2 antibody Integrin, alpha 2 (CD49B alpha 2 subunit of VLA 2 receptor) antibody ITA2_HUMAN antibody ITGA2 antibody Platelet alloantigen Br(a), included antibody Platelet antigen Br antibody Platelet glycoprotein GPIa antibody Platelet glycoprotein Ia antibody Platelet glycoprotein Ia/IIa antibody Platelet membrane glycoprotein Ia antibody Platelet receptor for collagen, deficiency of, included antibody Very late activation protein 2 receptor alpha 2 subunit antibody VLA 2 alpha chain antibody VLA 2 antibody VLA 2 subunit alpha antibody VLA-2 subunit alpha antibody VLA2 antibody VLA2 receptor alpha 2 subunit antibody VLAA2 antibody Accession No. Swiss-Prot#:P17301 Calculated MW 150 kDa Formulation 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. Storage Store at -20°C Application Details WB: 1:1,000-5,000 IHC: 1:50-1:200 ICC: 1:100-1:500 FC: 1:50-1:100 Images Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 1 Western blot analysis of ITGA2 on A431 cells lysates using anti-ITGA2 antibody at 1/1,000 dilution.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
    HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
    [Show full text]
  • Integrin Α2β1 in Nonactivated Conformation Can Induce Focal
    www.nature.com/scientificreports OPEN Integrin α2β1 in nonactivated conformation can induce focal adhesion kinase signaling Received: 17 February 2017 Maria Salmela1, Johanna Jokinen1,2, Silja Tiitta1, Pekka Rappu1, R. Holland Cheng 2 & Jyrki Accepted: 2 May 2017 Heino1 Published: xx xx xxxx Conformational activation of integrins is generally required for ligand binding and cellular signalling. However, we have previously reported that the nonactivated conformation of α2β1 integrin can also bind to large ligands, such as human echovirus 1. In this study, we show that the interaction between the nonactivated integrin and a ligand resulted in the activation of focal adhesion kinase (FAK) in a protein kinase C dependent manner. A loss-of-function mutation, α2E336A, in the α2-integrin did not prevent the activation of FAK, nor did EDTA-mediated inactivation of the integrin. Full FAK activation was observed, since phosphorylation was not only confirmed in residue Y397, but also in residues Y576/7. Furthermore, initiation of downstream signaling by paxillin phosphorylation in residue Y118 was evident, even though this activation was transient by nature, probably due to the lack of talin involvement in FAK activation and the absence of vinculin in the adhesion complexes formed by the nonactivated integrins. Altogether these results indicate that the nonactivated integrins can induce cellular signaling, but the outcome of the signaling differs from conventional integrin signaling. The well-established model of integrin function stresses the importance of the conformational change from a nonactivated, bent conformation to an active, extended state prior to ligand binding and outside-in signaling1. Despite the fact that the conformational activation of integrins is often required for ligand binding, nonactivated integrins may have specific biological functions as well.
    [Show full text]
  • Anti-Cd49a / Integrin Alpha 1 Antibody (ARG57529)
    Product datasheet [email protected] ARG57529 Package: 50 μg anti-CD49a / Integrin alpha 1 antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes CD49a / Integrin alpha 1 Tested Reactivity Hu Tested Application WB Host Goat Clonality Polyclonal Isotype IgG Target Name CD49a / Integrin alpha 1 Antigen Species Human Immunogen Synthetic peptide around the internal region of Human CD49a / Integrin alpha 1. (C-DKHDFQDSVRIT) Conjugation Un-conjugated Alternate Names VLA-1; CD49a; Integrin alpha-1; Laminin and collagen receptor; VLA1; CD antigen CD49a; CD49 antigen- like family member A Application Instructions Application table Application Dilution WB 0.3 - 1 µg/ml Application Note WB: Recommend incubate at RT for 1h. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 131 kDa (NP_852478.1) Observed Size 150 kDa (glycosylated form) Properties Form Liquid Purification Ammonium sulphate precipitation followed by affinity purification with immunogen. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA. Preservative 0.02% Sodium azide Stabilizer 0.5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGA1 Gene Full Name integrin, alpha 1 Background This gene encodes the alpha 1 subunit of integrin receptors.
    [Show full text]
  • 0268D98d499c00a44e5d919f5d
    Hindawi Publishing Corporation Stem Cells International Volume 2016, Article ID 5184601, 18 pages http://dx.doi.org/10.1155/2016/5184601 Research Article Phenotypic and Functional Characterization of Mesenchymal Stem/Multipotent Stromal Cells from Decidua Basalis of Human Term Placenta F. M. Abomaray,1,2,3 M. A. Al Jumah,1 K. O. Alsaad,4 D. Jawdat,1 A. Al Khaldi,5 A. S. AlAskar,1 S. Al Harthy,6 A. M. Al Subayyil,1 T. Khatlani,1 A. O. Alawad,6 A. Alkushi,4,7 B. Kalionis,8 and M. H. Abumaree1,7 1 King Abdullah International Medical Research Center, Mail Code 1515, P.O. Box 22490, Riyadh 11426, Saudi Arabia 2Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska Institutet, 14186 Stockholm, Sweden 3Center for Hematology and Regenerative Medicine, Karolinska Institutet, 14186 Stockholm, Sweden 4King Abdulaziz Medical City, Department of Pathology, P.O. Box 22490, Riyadh 11426, Saudi Arabia 5King Abdulaziz Medical City, Division of Cardiac Surgery, P.O. Box 22490, Riyadh, Saudi Arabia 6National Center for Stem Cell Technology, Life Sciences and Environment Research Institute, King Abdulaziz City for Science and Technology, P.O. Box 6086, Riyadh 11442, Saudi Arabia 7College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Mail Code 3124, P.O. Box 3660, Riyadh 11481, Saudi Arabia 8Department of Obstetrics and Gynaecology, University of Melbourne and Department of Perinatal Medicine Pregnancy Research Centre, Royal Women’s Hospital, Parkville, VIC 3052, Australia Correspondence should be addressed to M. H. Abumaree; [email protected] Received 5 November 2015; Revised 14 December 2015; Accepted 5 January 2016 Academic Editor: Albert Rizvanov Copyright © 2016 F.
    [Show full text]
  • Laminin-Binding Integrin A7,1: Functional Characterization and Expression in Normal and Malignant Melanocytes
    CELL REGULATION, Vol. 2, 805-817, October 1991 Laminin-binding integrin a7,1: functional characterization and expression in normal and malignant melanocytes Randall H. Kramer,*t$ Mai P. Vu,* increased attachment to laminin exhibit much Yao-Fen Cheng,* Daniel M. Ramos,* higher metastatic potential in lung colonization Rupert Timpl,§ and Nahid Waleh 11 assays (reviewed in Liotta et aL, 1986). Fur- *Departments of Stomatology and Anatomy thermore, the presence of intact laminin will en- and the tCardiovascular Research Institute hance lung colonization (Barsky et aL., 1984). University of California These results and others strongly suggest that San Francisco, California 94143 melanoma cells interact with laminin-rich base- §Max-Planck-lnstitut fur Biochemie ment membrane and that this interaction facil- Martinsried, Germany itates their vascular arrest and colonization of IISRI International distant sites. Menlo Park, California 94025 During tissue invasion, metastatic melanoma cells interact with different types of extracellular matrix, including the interstitium and basement A novel integrin, a,#,, that specifically binds with membranes. It is expected, then, that these high affinity to laminin has been identified on mel- malignant cells will express surface adhesion anoma cells. This complex was purified from both receptors with diverse ligand specificities human and murine melanoma cells by laminin-af- (Ruoslahti and Giancotti, 1989). The integrin finity chromatography, and the a7 subunit was re- family of adhesion receptors consists of a large covered after gel electrophoresis. N-terminal amino number of heterodimer receptors that appear acid sequence analysis of the a7 subunit from both to mediate many of the cell-extracellular matrix human and mouse cells verifies that this integrin interactions for melanoma and other cell types is distinct from other a chains in the #I family, al- (Hynes, 1987; Ruoslahti and Pierschbacher, though strikingly similar to the as subunit.
    [Show full text]
  • Anti-CD18 / LFA1 Beta Antibody (ARG41484)
    Product datasheet [email protected] ARG41484 Package: 100 μl anti-CD18 / LFA1 beta antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CD18 / LFA1 beta Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CD18 / LFA1 beta Antigen Species Human Immunogen Recombinant protein of Human CD18 / LFA1 beta. Conjugation Un-conjugated Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse thymus Calculated Mw 85 kDa Observed Size ~ 98 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw www.arigobio.com 1/3 cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGB2 Gene Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Background This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers.
    [Show full text]